Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)—A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, recruitment, and baseline characteristics
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Patients with prior vascular disease remain at high risk for cardiovascular events despite intensive statin-based treatment. Inhibition of cholesteryl ester transfer protein by anacetrapib reduces low-density lipoprotein (LDL) cholesterol by around 25% to 40% and more than doubles high-density lipoprotein (HDL) cholesterol. However, it is not known if these apparently favorable lipid changes translate into reductions in cardiovascular events. METHODS: The REVEAL study is a randomized, double-blind, placebo-controlled clinical trial that is assessing the efficacy and safety of adding anacetrapib to effective LDL-lowering treatment with atorvastatin for an average of at least 4years among patients with preexisting atherosclerotic vascular disease. The primary assessment is an intention-to-treat comparison among all randomized participants of the effects of allocation to anacetrapib on major coronary events (defined as the occurrence of coronary death, myocardial infarction, or coronary revascularization). RESULTS: Between August 2011 and October 2013, 30,449 individuals in Europe, North America, and China were randomized to receive anacetrapib 100mg daily or matching placebo. Mean (SD) age was 67 (8) years, 84% were male, 88% had a history of coronary heart disease, 22% had cerebrovascular disease, and 37% had diabetes mellitus. At the randomization visit (after at least 8weeks on a protocol-defined atorvastatin regimen), mean plasma LDL cholesterol was 61 (15) mg/dL and HDL cholesterol was 40 (10) mg/dL. INTERPRETATION: The REVEAL trial will provide a robust evaluation of the clinical efficacy and safety of adding anacetrapib to an effective statin regimen. Results are anticipated in 2017.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139 · cited 2×
“07 Medication ACE inhibitor or ARB 11,879 (75%) 4400 (72%) 4050 (47%) 20,329 (67%) Antiplatelet therapy 14,261 (91%) 5654 (93%) 7992 (93%) 27,907 (92%) Diuretic 3965 (25%) 1831 (30%) 728 (8%) 6524 (21%) Calcium-channel blocker 4045 (26%) 1461 (24%) 2679 (31%) 8185 (27%) β-Blocker 10,897 (69%) 4665 (77%) 5112 (59%) 20,…”
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Major lipids, apolipoproteins, and risk of vascular disease
The Emerging Risk Factors Collaboration* (2009) · JAMA · doi:10.1001/jama.2009.1619 · Cited by 2,731
Pocock, S. J., & Simon, R. (1975) · Biometrics · doi:10.2307/2529712 · Cited by 2,350
Effects of dalcetrapib in patients with a recent acute coronary syndrome
Schwartz, G. G., Olsson, A. G., Abt, M., Ballantyne, C. M., Barter, P. J., Brumm, J., Chaitman, B. R., Holme, I. M., Kallend, D., Leiter, L. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1206797 · Cited by 2,022 · cited 2×
“07 Medication ACE inhibitor or ARB 11,879 (75%) 4400 (72%) 4050 (47%) 20,329 (67%) Antiplatelet therapy 14,261 (91%) 5654 (93%) 7992 (93%) 27,907 (92%) Diuretic 3965 (25%) 1831 (30%) 728 (8%) 6524 (21%) Calcium-channel blocker 4045 (26%) 1461 (24%) 2679 (31%) 8185 (27%) β-Blocker 10,897 (69%) 4665 (77%) 5112 (59%) 20,…”
Effects of extended-release niacin with laropiprant in high-risk patients
The HPS2-THRIVE Collaborative Group (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1300955 · Cited by 1,668
Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis
Jun, M., Foote, C., Lv, J., Neal, B., Patel, A., Nicholls, S. J., Grobbee, D. E., Cass, A., Chalmers, J., & Perkovic, V. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60656-3 · Cited by 927 · cited 1×
“73 m(2))‡ 81 ± 17 80 ± 18 90 ± 15 83 ± 17 Urinary albumin/creatinine ratio (mg/g) 8 (4-21) 8 (4-29) 8 (4-23) 8 (4-23)”
Safety of anacetrapib in patients with or at high risk for coronary heart disease
Cannon, C. P., Shah, S., Dansky, H. M., Davidson, M., Brinton, E. A., Gotto, A. M., Stepanavage, M., Liu, S. X., Gibbons, P., Ashraf, T. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1009744 · Cited by 749 · cited 3×
“07 Medication ACE inhibitor or ARB 11,879 (75%) 4400 (72%) 4050 (47%) 20,329 (67%) Antiplatelet therapy 14,261 (91%) 5654 (93%) 7992 (93%) 27,907 (92%) Diuretic 3965 (25%) 1831 (30%) 728 (8%) 6524 (21%) Calcium-channel blocker 4045 (26%) 1461 (24%) 2679 (31%) 8185 (27%) β-Blocker 10,897 (69%) 4665 (77%) 5112 (59%) 20,…”
BackgroundNicholls, S. J., Brewer, H. B., Kastelein, J. J. P., Krueger, K. A., Wang, M.-D., Shao, M., Hu, B., McErlean, E., & Nissen, S. E. (2011) · JAMA · doi:10.1001/jama.2011.1649 · Cited by 410 · cited 2×
“07 Medication ACE inhibitor or ARB 11,879 (75%) 4400 (72%) 4050 (47%) 20,329 (67%) Antiplatelet therapy 14,261 (91%) 5654 (93%) 7992 (93%) 27,907 (92%) Diuretic 3965 (25%) 1831 (30%) 728 (8%) 6524 (21%) Calcium-channel blocker 4045 (26%) 1461 (24%) 2679 (31%) 8185 (27%) β-Blocker 10,897 (69%) 4665 (77%) 5112 (59%) 20,…”
Heart Protection Study Collaborative Group (2011) · The Lancet · doi:10.1016/s0140-6736(11)61125-2 · Cited by 373 · cited 2×
“07 Medication ACE inhibitor or ARB 11,879 (75%) 4400 (72%) 4050 (47%) 20,329 (67%) Antiplatelet therapy 14,261 (91%) 5654 (93%) 7992 (93%) 27,907 (92%) Diuretic 3965 (25%) 1831 (30%) 728 (8%) 6524 (21%) Calcium-channel blocker 4045 (26%) 1461 (24%) 2679 (31%) 8185 (27%) β-Blocker 10,897 (69%) 4665 (77%) 5112 (59%) 20,…”
Ford, I., Murray, H., McCowan, C., & Packard, C. J. (2016) · Circulation · doi:10.1161/circulationaha.115.019014 · Cited by 238
Gotto, A. M., Cannon, C. P., Li, X. S., Vaidya, S., Kher, U., Brinton, E. A., Davidson, M., Moon, J. E., Shah, S., Dansky, H. M., et al. (2014) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2013.08.041 · Cited by 86 · cited 2×
“07 Medication ACE inhibitor or ARB 11,879 (75%) 4400 (72%) 4050 (47%) 20,329 (67%) Antiplatelet therapy 14,261 (91%) 5654 (93%) 7992 (93%) 27,907 (92%) Diuretic 3965 (25%) 1831 (30%) 728 (8%) 6524 (21%) Calcium-channel blocker 4045 (26%) 1461 (24%) 2679 (31%) 8185 (27%) β-Blocker 10,897 (69%) 4665 (77%) 5112 (59%) 20,…”
Measurement of LDL-C after treatment with the CETP inhibitor anacetrapib
Davidson, M., Liu, S. X., Barter, P., Brinton, E. A., Cannon, C. P., Gotto, A. M., Leary, E. T., Shah, S., Stepanavage, M., Mitchel, Y., et al. (2013) · Journal of Lipid Research · doi:10.1194/jlr.m032615 · Cited by 56 · cited 2×
“07 Medication ACE inhibitor or ARB 11,879 (75%) 4400 (72%) 4050 (47%) 20,329 (67%) Antiplatelet therapy 14,261 (91%) 5654 (93%) 7992 (93%) 27,907 (92%) Diuretic 3965 (25%) 1831 (30%) 728 (8%) 6524 (21%) Calcium-channel blocker 4045 (26%) 1461 (24%) 2679 (31%) 8185 (27%) β-Blocker 10,897 (69%) 4665 (77%) 5112 (59%) 20,…”
Cited by
Effects of anacetrapib in patients with atherosclerotic vascular disease
The HPS3/TIMI55–REVEAL Collaborative Group (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706444 · Cited by 1,047
Ference, B. A., Kastelein, J. J. P., Ginsberg, H. N., Chapman, M. J., Nicholls, S. J., Ray, K. K., Packard, C. J., Laufs, U., Brook, R. D., Oliver-Williams, C., et al. (2017) · JAMA · doi:10.1001/jama.2017.11467 · Cited by 304
Bergheanu, S. C., Bodde, M. C., & Jukema, J. W. (2017) · Netherlands Heart Journal · doi:10.1007/s12471-017-0959-2 · Cited by 282
Lipid management in patients with chronic kidney disease
Ferro, C. J., Mark, P. B., Kanbay, M., Sarafidis, P., Heine, G. H., Rossignol, P., Massy, Z. A., Mallamaci, F., Valdivielso, J. M., Malyszko, J., et al. (2018) · Nature Reviews Nephrology · doi:10.1038/s41581-018-0072-9 · Cited by 273
Cholesteryl Ester Transfer Protein Inhibition for Preventing Cardiovascular Events
Armitage, J., Holmes, M. V., & Preiss, D. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.10.072 · Cited by 140
“From 2011 to 2013, 30,449 patients with stable atherosclerotic vascular disease were randomized to anacetrapib 100 mg daily or matching placebo in the REVEAL study (35,36).”
Background
Metadata
- Authors
- Landray, M. J., & REVEAL Collaborative Group
- Venue
- American Heart Journal
- Publisher
- Elsevier BV
- Published
- 2017-05
- Volume
- 187
- Pages
- 182-190
- ISSN
- 0002-8703 (ISSN-L)
- OpenAlex
- W2590875878
- Cited by
- 68
- References
- 16
- FWCI
- 8.84
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.